drugset / Trial / NCT01775631
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Rituximab in patients with B-cell Non-Hodgkins Lymphoma
Timeline
- Start
- 2013-03
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Urelumab | Monoclonal antibody | — | Intravenous |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |